MiMedx (MDXG) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +55.56%. A quarter ago, it was expected that this developer of biomaterials made from sterilized human amniotic membrane would post earnings of $0.07 per share when it actually produced earnings of $0.15, delivering a surpr ...

MiMedx Group (NasdaqCM:MDXG) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsDoug Rice - CFOJoe Capper - CEOMatt Notarianni - Head of Investor RelationsConference Call ParticipantsBradley Bowers - AnalystChase Knickerbocker - Senior Research AnalystDavid Turcotte - Equity Research AnalystFrank Takkinen - Senior Research AnalystOperatorGood afternoon, and thank you for standing by. Welcome to the MiMedx fourth quarter and full year 2025 operating and financial results conference call. ...

MiMedx Group (NasdaqCM:MDXG) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker7Good afternoon, and thank you for standing by. Welcome to the MiMedx fourth quarter and full year 2025 operating and financial results conference call. At this time, all participants are in listen-only mode. The question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. Matt Notarianni, Head of Investor ...

MARIETTA, Ga., February 25, 2026 -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the fourth quarter and full year 2025. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "MIMEDX delivered a record year of revenue and profitability in 2025, with fourth quarter results that included net sales growth of 27% year- over-year, net income of $15 million, an Adjusted EBITDA margin of 25% of net sales, and robust free cash flow. These r ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to __________ Commission file number 001-35887 (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I ...

Net Sales Grew 27% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $15 million and $0.10, Respectively Fourth Quarter Adjusted EBITDA1 was $29 Million, or 25% of Net Sales Company Estimates 2026 Net Sales in a Range of $340-360 Million Announces $100 Million Share Repurchase Program Authorization Management to Host Conference Call Today, February 25, 2026, at 4:30 PM ET MARIETTA, Ga., Feb. 25, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, I ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.Considering buying MDXG stock? Here’s what analysts think: Photo via Shutterstock ...

MARIETTA, Ga., Feb. 17, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the fourth quarter and full year ended December 31, 2025 after the market close on Wednesday, February 25, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following informa ...

Core Viewpoint - MiMedx Group, Inc. has entered into an exclusive distribution agreement with Summit Products Group to expand its product offerings in the Surgical & Wound markets with three innovative products: Hydrelix, NovaForm, and G4Derm Plus [1][2]. Company Overview - MiMedx is a leader in providing healing solutions, focusing on chronic and hard-to-heal wounds, with a vision to be the leading global provider through relentless innovation [3]. - Summit Products Group specializes in advancing surgical and regenerative solutions, emphasizing innovation and regulatory compliance to deliver breakthrough products to healthcare providers [4]. Product Details - Hydrelix is a sterile, Type 1 collagen powder made from soluble modified bovine collagen, designed for efficient therapeutic effects at the wound site [5]. - NovaForm is a proprietary bioglass and collagen-based wound dressing for managing various types of wounds, maintaining a moist environment to support natural healing [5]. - G4Derm Plus is a flowable peptide matrix that mimics the human extracellular matrix, providing rapid wound closure while controlling bioburden [5].

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. MiMedx Group, Inc. (NASDAQ:MDXG) is on our list of best biotech stocks. TheFly reported on January 23 that Craig-Hallum analyst Chase Knickerbocker lowered the price target on MDXG to $10 from $13 and maintained a Buy rating. The revision followed recent CMS guidance on provider billing and the withdrawal of the local coverage determination, which the firm expects to create provider confusion and pressure wound care volumes in ...